16.02.2023 - - Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) observed and encouraging patient reported outcome data in all dose cohorts in ENPP1 Deficiency trial - - Rapid and significant increase in PPi observed in all dose cohorts .
15.08.2022 - - Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency – - Appointed Kurt Gunter, M.D. as senior vice president and chief medical officer - - .
The administration is working to ensure vaccines will be available at health centers, rural health clinics, children's hospitals and pharmacies to ensure access.